Lexaria Bioscience Corp. income statement LEXX

Annual Quarterly

In fiscal 2025, which ended Aug 31, 2025, Lexaria Bioscience Corp. reported revenue of $705,923, up 52.0% from the year before. It recorded a net loss of $11.9 million. The operating loss came to $11.9 million, an operating margin of -1683.0%. Diluted earnings per share were -$0.66. Over the twelve months ended May 31, 2026, revenue was $194,000 and the net loss was $7.7 million. Across the 8 fiscal years shown, revenue grew from $433,287 in fiscal 2018 to $705,923 in fiscal 2025, about 7.2% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 May 31, 2026	FY 2025 Aug 31, 2025	FY 2024 Aug 31, 2024	FY 2023 Aug 31, 2023	FY 2022 Aug 31, 2022	FY 2021 Aug 31, 2021	FY 2020 Aug 31, 2020	FY 2019 Aug 31, 2019	FY 2018 Aug 31, 2018	FY 2015 Aug 31, 2015	FY 2011 Oct 31, 2011
Revenue	0 -68.5%	1 +52.0%	0 +105.2%	0 -11.4%	0 -64.7%	1 +87.9%	0 +72.7%	0 -48.6%	0	—	—
Cost of revenue	0 -100.0%	0 -43.6%	0 -84.7%	0 -56.2%	0 -59.0%	0 +76.4%	0 +334.1%	0 -9.1%	0 -15.3%	0	1
Gross profit	0 -68.4%	1 +53.1%	0 +136.0%	0 +6.1%	0 -66.5%	1 +154.1%	0 +7.9%	0 -51.1%	0 +1104.2%	-0	0
Research and development	4 -45.4%	8 +249.0%	2 -35.6%	4 +99.0%	2 +45.9%	1 +226.3%	0 -30.3%	1 +12.8%	0 +809.6%	0	—
Selling, general and administrative	4 -16.7%	4 +12.8%	4 +25.8%	3 -38.3%	5 -0.2%	5 +25.0%	4 +1238.2%	0 +36.6%	0 +67.8%	0 +62.0%	0
Operating expenses	8 -34.2%	13 +102.6%	6 -7.7%	7 -1.1%	7	—	—	—	—	—	—
Operating income	-8 +32.4%	-12 -106.5%	-6 +12.0%	-7 +1.3%	-7	—	—	—	—	-2	—
Interest income	0	0 -78.9%	0 -66.9%	0	—	—	—	—	—	—	—
Other income (expense)	-0	-0	—	—	—	—	—	—	—	—	—
Pretax income	—	-12 -105.1%	-6 +13.5%	-7 +9.1%	-7 -77.1%	-4 -4.6%	-4 +4.1%	-4 +37.1%	-7	—	—
Income tax	—	—	—	—	0 -100.0%	0 +162.7%	0 -86.9%	0	0	—	—
Net income	-8 +32.1%	-12 -105.4%	-6 +13.0%	-7 +8.3%	-7 -80.5%	-4 +1.4%	-4 +1.8%	-4 +37.1%	-7	-2	-1
Diluted EPS	-0.34	-0.66 -40.4%	-0.47	—	—	—	—	—	—	—	-0.04
Weighted average shares, diluted	23	18 +45.3%	12	—	—	—	—	—	—	—	14
Other measures
Depreciation and amortization	0	0 -32.7%	0 -47.6%	0 +41.5%	0 -8.1%	0 -0.9%	0 +86.2%	0 +2524.6%	0 +55.0%	—	0
EBITDA	-8	-12 -108.4%	-6 +11.1%	-6 +2.0%	-7	—	—	—	—	—	—
Interest coverage	—	—	—	—	—	—	—	—	—	-62.87x	—
Margins
Gross margin	100.00%	99.61%	98.96%	86.07%	71.87%	75.74%	56.02%	89.72%	94.19%	—	—
Operating margin	-3,973.16%	-1,683.01%	-1,239.16%	-2,888.50%	-2,591.67%	—	—	—	—	—	—
Pretax margin	—	-1,687.36%	-1,251.12%	-2,967.41%	-2,891.05%	-576.95%	-1,036.82%	-1,868.03%	-1,525.36%	—	—
Profit margin	-3,985.58%	-1,686.00%	-1,248.25%	-2,946.36%	-2,846.28%	-557.19%	-1,062.20%	-1,868.03%	-1,525.36%	—	—
EBITDA margin	-3,946.39%	-1,675.75%	-1,222.75%	-2,824.23%	-2,551.45%	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: LEXX (Nasdaq)
Fiscal year ends: August 31
Incorporated in: NV
Headquarters: Kelowna, British Columbia, Canada
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1348362
Former names: Lexaria Corp. (until May 11, 2016); LEXARIA CORP. (until May 11, 2016)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.